Particularly, the IL-6R/JAK/STAT3 pathway largely contributes to the MM multistep transformation process and pathogenesis, making its therapeutic targeting an attractive strategy that could favor durable remissions in MM patients [33–36]. This evidence concerns the gene STAT3 and Miyoshi myopathy.